The challenges in primary sclerosing cholangitis - Aetiopathogenesis, autoimmunity, management and malignancy

Journal of Hepatology

Volumn 48, Issue SUPPL. 1, 2008, Pages

  Weismüller, Tobias J ^a   Wedemeyer, Jochen ^a   Kubicka, Stefan ^a   Strassburg, Christian P ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Aetiology; Cholangiocarcinoma; Diagnosis; Immunology; Malignancy; Pathogenesis; Primary sclerosing cholangitis; PSC; Surveillance; Therapy; Transplantation

Indexed keywords

GEMCITABINE; PLACEBO; PLATINUM DERIVATIVE; URSODEOXYCHOLIC ACID;

AUTOIMMUNE DISEASE; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILE DUCT DISEASE; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CHOLANGITIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; GENETIC DISORDER; HISTOLOGY; HUMAN; IMMUNOGENICITY; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; SEROLOGY; SEX DIFFERENCE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; HUMANS; LIVER TRANSPLANTATION; PREVALENCE;

EID: 40849123925     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.01.020     Document Type: Review

References (189)

1. Bargen J. Complications and sequelae of chronic ulcerative colitis. Ann Intern Med 3 (1929) 335-352
2. Kimmelstiel P., Large Jr. H.L., and Verner H.D. Liver damage in ulcerative colitis. Am J Pathol 28 (1952) 259-289
3. Schrumpf E., and Boberg K.M. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15 (2001) 553-562
4. Boberg K.M., Aadland E., Jahnsen J., Raknerud N., Stiris M., and Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33 (1998) 99-103
5. Kaplan G.G., Laupland K.B., Butzner D., Urbanski S.J., and Lee S.S. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 102 (2007) 1042-1049
6. Bambha K., Kim W.R., Talwalkar J., Torgerson H., Benson J.T., Therneau T.M., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125 (2003) 1364-1369
7. Kingham J.G., Kochar N., and Gravenor M.B. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 126 (2004) 1929-1930
8. Escorsell A., Pares A., Rodes J., Solis-Herruzo J.A., Miras M., and de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 21 (1994) 787-791
9. Ang T.L., Fock K.M., Ng T.M., Teo E.K., Chua T.S., and Tan J.Y. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 17 (2002) 908-913
10. Takikawa H., Takamori Y., Tanaka A., Kurihara H., and Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 29 (2004) 153-159
11. Hurlburt K.J., McMahon B.J., Deubner H., Hsu-Trawinski B., Williams J.L., and Kowdley K.V. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 97 (2002) 2402-2407
12. Olsson R., Danielsson A., Jarnerot G., Lindstrom E., Loof L., Rolny P., et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 100 (1991) 1319-1323
13. Mitchell S.A., Thyssen M., Orchard T.R., Jewell D.P., Fleming K.A., and Chapman R.W. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 51 (2002) 567-573
14. Loftus Jr. E.V., Sandborn W.J., Tremaine W.J., Mahoney D.W., Zinsmeister A.R., Offord K.P., et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 110 (1996) 1496-1502
15. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L., Danielsson A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36 (2002) 321-327
16. Broome U., Olsson R., Loof L., Bodemar G., Hultcrantz R., Danielsson A., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38 (1996) 610-615
17. Tischendorf J.J., Hecker H., Kruger M., Manns M.P., and Meier P.N. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 102 (2007) 107-114
18. O'Mahony C.A., and Vierling J.M. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 26 (2006) 3-21
19. Worthington J., Cullen S., and Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 28 (2005) 93-103
20. Saarinen S., Olerup O., and Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 95 (2000) 3195-3199
21. Bergquist A., Lindberg G., Saarinen S., and Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 42 (2005) 252-256
22. Donaldson P.T. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 53 (2004) 599-608
23. Norris S., Kondeatis E., Collins R., Satsangi J., Clare M., Chapman R., et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 120 (2001) 1475-1482
24. Donaldson P.T., and Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 35 (2002) 555-564
25. Spurkland A., Saarinen S., Boberg K.M., Mitchell S., Broome U., Caballeria L., et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 53 (1999) 459-469
26. Henckaerts L., Fevery J., Van Steenbergen W., Verslype C., Yap P., Nevens F., et al. CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis. Inflamm Bowel Dis 12 (2006) 272-277
27. Eri R., Jonsson J.R., Pandeya N., Purdie D.M., Clouston A.D., Martin N., et al. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 5 (2004) 444-450
28. Yang X., Cullen S.N., Li J.H., Chapman R.W., and Jewell D.P. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 40 (2004) 375-379
29. Bowlus C.L., Karlsen T.H., Broome U., Thorsby E., Vatn M., Schrumpf E., et al. Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. J Hepatol 45 (2006) 704-710
30. Mitchell S.A., Grove J., Spurkland A., Boberg K.M., Fleming K.A., Day C.P., et al. Association of the tumour necrosis factor alpha-308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 49 (2001) 288-294
31. Gallegos-Orozco J.F., Yurk C.E., Wang N., Rakela J., Charlton M.R., Cutting G.R., et al. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol 100 (2005) 874-878
32. Sheth S., Shea J.C., Bishop M.D., Chopra S., Regan M.M., Malmberg E., et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 113 (2003) 286-292
33. Angulo P., Peter J.B., Gershwin M.E., DeSotel C.K., Shoenfeld Y., Ahmed A.E., et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 32 (2000) 182-187
34. Mulder A.H., Horst G., Haagsma E.B., Limburg P.C., Kleibeuker J.H., and Kallenberg C.G. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 17 (1993) 411-417
35. Bansi D.S., Fleming K.A., and Chapman R.W. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 38 (1996) 384-389
36. Terjung B., and Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol 28 (2005) 115-133
37. Terjung B., Spengler U., Sauerbruch T., and Worman H.J. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119 (2000) 310-322
38. Bodenheimer Jr. H.C., LaRusso N.F., Thayer Jr. W.R., Charland C., Staples P.J., and Ludwig J. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology 3 (1983) 150-154
39. Senaldi G., Donaldson P.T., Magrin S., Farrant J.M., Alexander G.J., Vergani D., et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 97 (1989) 1430-1434
40. Bo X., Broome U., Remberger M., and Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 49 (2001) 131-141
41. Grant A.J., Lalor P.F., Salmi M., Jalkanen S., and Adams D.H. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359 (2002) 150-157
42. Eksteen B., Miles A.E., Grant A.J., and Adams D.H. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med 4 (2004) 173-180
43. Salmi M., and Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis 4 (1998) 149-156
44. Grant A.J., Lalor P.F., Hubscher S.G., Briskin M., and Adams D.H. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 33 (2001) 1065-1072
45. Eksteen B., Grant A.J., Miles A., Curbishley S.M., Lalor P.F., Hubscher S.G., et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 200 (2004) 1511-1517
46. Palmer K.R., Duerden B.I., and Holdsworth C.D. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut 21 (1980) 851-854
47. Ludwig J., Barham S.S., LaRusso N.F., Elveback L.R., Wiesner R.H., and McCall J.T. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1 (1981) 632-640
48. Lichtman S.N., Sartor R.B., Keku J., and Schwab J.H. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 98 (1990) 414-423
49. Bjornsson E., Cederborg A., Akvist A., Simren M., Stotzer P.O., and Bjarnason I. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol 40 (2005) 1090-1094
50. Nilsson H.O., Taneera J., Castedal M., Glatz E., Olsson R., and Wadstrom T. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 38 (2000) 1072-1076
51. Boomkens S.Y., de Rave S., Pot R.G., Egberink H.F., Penning L.C., Rothuizen J., et al. The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis. FEMS Immunol Med Microbiol 44 (2005) 221-225
52. Krasinskas A.M., Yao Y., Randhawa P., Dore M.P., and Sepulveda A.R. Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci 52 (2007) 2265-2270
53. Mehal W.Z., Hattersley A.T., Chapman R.W., and Fleming K.A. A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive polymerase chain reaction (PCR) based assay. J Hepatol 15 (1992) 396-399
54. Minuk G.Y., Rascanin N., Paul R.W., Lee P.W., Buchan K., and Kelly J.K. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 5 (1987) 8-13
55. Pohl J., Ring A., Stremmel W., and Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 18 (2006) 69-74
56. Bjornsson E.S., Kilander A.F., and Olsson R.G. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis - a study of bile cultures from ERCP. Hepatogastroenterology 47 (2000) 1504-1508
57. Kulaksiz H., Rudolph G., Kloeters-Plachky P., Sauer P., Geiss H., and Stiehl A. Biliary Candida infections in primary sclerosing cholangitis. J Hepatol 45 (2006) 711-716
58. Tietz P.S., and Larusso N.F. Cholangiocyte biology. Curr Opin Gastroenterol 22 (2006) 279-287
59. Lazaridis K.N., Strazzabosco M., and Larusso N.F. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 127 (2004) 1565-1577
60. Trauner M., Meier P.J., and Boyer J.L. Molecular pathogenesis of cholestasis. N Engl J Med 339 (1998) 1217-1227
61. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130 (2006) 465-481
62. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Weiglein A.H., Lammert F., et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123 (2002) 1238-1251
63. Pauli-Magnus C., Kerb R., Fattinger K., Lang T., Anwald B., Kullak-Ublick G.A., et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 39 (2004) 779-791
64. Das K.M., Vecchi M., and Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 98 (1990) 464-469
65. Mandal A., Dasgupta A., Jeffers L., Squillante L., Hyder S., Reddy R., et al. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology 106 (1994) 185-192
66. Xu B., Broome U., Ericzon B.G., and Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 51 (2002) 120-127
67. Karrar A., Broome U., Sodergren T., Jaksch M., Bergquist A., Bjornstedt M., et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 132 (2007) 1504-1514
68. Spirli C., Nathanson M.H., Fiorotto R., Duner E., Denson L.A., Sanz J.M., et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 121 (2001) 156-169
69. Spirli C., Fabris L., Duner E., Fiorotto R., Ballardini G., Roskams T., et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124 (2003) 737-753
70. Fevery J., Verslype C., Lai G., Aerts R., and Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 52 (2007) 3123-3135
71. Komichi D., Tazuma S., Nishioka T., Hyogo H., and Chayama K. Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. Free Radic Biol Med 39 (2005) 1418-1427
72. Meng F., Yamagiwa Y., Ueno Y., and Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 44 (2006) 1055-1065
73. Ahrendt S.A., Rashid A., Chow J.T., Eisenberger C.F., Pitt H.A., and Sidransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 7 (2000) 426-431
74. Boberg K.M., Schrumpf E., Bergquist A., Broome U., Pares A., Remotti H., et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 32 (2000) 374-380
75. Taniai M., Higuchi H., Burgart L.J., and Gores G.J. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 123 (2002) 1090-1098
76. Ahrendt S.A., Eisenberger C.F., Yip L., Rashid A., Chow J.T., Pitt H.A., et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 84 (1999) 88-93
77. Wiesner R.H., Grambsch P.M., Dickson E.R., Ludwig J., MacCarty R.L., Hunter E.B., et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10 (1989) 430-436
78. Bergquist A., Said K., and Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 42 (2007) 88-93
79. Talwalkar J.A., and Lindor K.D. Primary sclerosing cholangitis. Inflamm Bowel Dis 11 (2005) 62-72
80. Zein C.O., Lindor K.D., and Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 39 (2004) 204-210
81. Bjornsson E., Simren M., Olsson R., and Chapman R.W. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 39 (2004) 961-968
82. Bergquist A., Glaumann H., Persson B., and Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27 (1998) 311-316
83. Hay J.E., Lindor K.D., Wiesner R.H., Dickson E.R., Krom R.A., and LaRusso N.F. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 14 (1991) 257-261
84. Lee Y.M., and Kaplan M.M. Primary sclerosing cholangitis. N Engl J Med 332 (1995) 924-933
85. Majoie C.B., Reeders J.W., Sanders J.B., Huibregtse K., and Jansen P.L. Primary sclerosing cholangitis: a modified classification of cholangiographic findings. AJR Am J Roentgenol 157 (1991) 495-497
86. Rajaram R., Ponsioen C.Y., Majoie C.B., Reeders J.W., and Lameris J.S. Evaluation of a modified cholangiographic classification system for primary sclerosing cholangitis. Abdom Imaging 26 (2001) 43-47
87. Wee A., and Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?. Ann Intern Med 102 (1985) 581-587
88. Trauner M., and Boyer J.L. Cholestatic syndromes. Curr Opin Gastroenterol 20 (2004) 220-230
89. Engler S., Elsing C., Flechtenmacher C., Theilmann L., Stremmel W., and Stiehl A. Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders. Gut 52 (2003) 688-693
90. Gelbmann C.M., Rummele P., Wimmer M., Hofstadter F., Gohlmann B., Endlicher E., et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 102 (2007) 1221-1229
91. Byrne M.F., Chong H.I., O'Donovan D., Sheehan K.M., Leader M.B., Kay E., et al. Idiopathic cholangiopathy in a biliary cast syndrome necessitating liver transplantation following head trauma. Eur J Gastroenterol Hepatol 15 (2003) 415-417
92. van Milligen de Wit A.W., van Bracht J., Rauws E.A., Jones E.A., Tytgat G.N., and Huibregtse K. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 44 (1996) 293-299
93. Stiehl A., Rudolph G., Kloeters-Plachky P., Sauer P., and Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 36 (2002) 151-156
94. van Milligen de Wit A.W., Rauws E.A., van Bracht J., Mulder C.J., Jones E.A., Tytgat G.N., et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 46 (1997) 344-347
95. Freeman M.L., Nelson D.B., Sherman S., Haber G.B., Herman M.E., Dorsher P.J., et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 335 (1996) 909-918
96. Loperfido S., Angelini G., Benedetti G., Chilovi F., Costan F., De Berardinis F., et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 48 (1998) 1-10
97. Masci E., Toti G., Mariani A., Curioni S., Lomazzi A., Dinelli M., et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 96 (2001) 417-423
98. Ernst O., Asselah T., Sergent G., Calvo M., Talbodec N., Paris J.C., et al. MR cholangiography in primary sclerosing cholangitis. AJR Am J Roentgenol 171 (1998) 1027-1030
99. Fulcher A.S., Turner M.A., Franklin K.J., Shiffman M.L., Sterling R.K., Luketic V.A., et al. Primary sclerosing cholangitis: evaluation with MR cholangiography - a case-control study. Radiology 215 (2000) 71-80
100. Angulo P., Pearce D.H., Johnson C.D., Henry J.J., LaRusso N.F., Petersen B.T., et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 33 (2000) 520-527
101. Moff S.L., Kamel I.R., Eustace J., Lawler L.P., Kantsevoy S., Kalloo A.N., et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 64 (2006) 219-223
102. Berstad A.E., Aabakken L., Smith H.J., Aasen S., Boberg K.M., and Schrumpf E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 4 (2006) 514-520
103. Textor H.J., Flacke S., Pauleit D., Keller E., Neubrand M., Terjung B., et al. Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 34 (2002) 984-990
104. Olsson R., Hagerstrand I., Broome U., Danielsson A., Jarnerot G., Loof L., et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 48 (1995) 933-935
105. Burak K.W., Angulo P., and Lindor K.D. Is there a role for liver biopsy in primary sclerosing cholangitis?. Am J Gastroenterol 98 (2003) 1155-1158
106. Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75 (2000) 688-694
107. Kim W.R., Ludwig J., and Lindor K.D. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 95 (2000) 1130-1138
108. Bjornsson E., Boberg K.M., Cullen S., Fleming K., Clausen O.P., Fausa O., et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 51 (2002) 731-735
109. Broome U., Glaumann H., Lindstom E., Loof L., Almer S., Prytz H., et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 36 (2002) 586-589
110. Angulo P., Maor-Kendler Y., and Lindor K.D. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 35 (2002) 1494-1500
111. Charatcharoenwitthaya P., Angulo P., Enders F.B., and Lindor K.D. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology 47 (2008) 133-142
112. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
113. van Buuren H.R., van Hoogstraten H.J.E., Terkivatan T., Schalm S.W., and Vleggaar F.P. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 33 (2000) 543-548
114. Kaya M., Angulo P., and Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 33 (2000) 537-542
115. Gregorio G.V., Portmann B., Karani J., Harrison P., Donaldson P.T., Vergani D., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33 (2001) 544-553
116. Floreani A., Rizzotto E.R., Ferrara F., Carderi I., Caroli D., Blasone L., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 100 (2005) 1516-1522
117. Kawa S., Hamano H., Umemura T., Kiyosawa K., and Uehara T. Sclerosing cholangitis associated with autoimmune pancreatitis. Hepatol Res 37 (2007) S487-S495
118. Nakanuma Y., and Zen Y. Pathology and immunopathology of immunoglobulin G4-related sclerosing cholangitis: the latest addition to the sclerosing cholangitis family. Hepatol Res 37 (2007) S478-S486
119. Zen Y., Harada K., Sasaki M., Sato Y., Tsuneyama K., Haratake J., et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis?. Am J Surg Pathol 28 (2004) 1193-1203
120. Mendes F.D., Jorgensen R., Keach J., Katzmann J.A., Smyrk T., Donlinger J., et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 101 (2006) 2070-2075
121. Dickson E.R., Murtaugh P.A., Wiesner R.H., Grambsch P.M., Fleming T.R., Ludwig J., et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103 (1992) 1893-1901
122. Nyblom H., Nordlinder H., and Olsson R. High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int 27 (2007) 694-699
123. Burak K., Angulo P., Pasha T.M., Egan K., Petz J., and Lindor K.D. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99 (2004) 523-526
124. Tischendorf J.J., Meier P.N., Strassburg C.P., Klempnauer J., Hecker H., Manns M.P., et al. Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 41 (2006) 1227-1234
125. Chalasani N., Baluyut A., Ismail A., Zaman A., Sood G., Ghalib R., et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31 (2000) 7-11
126. Brandsaeter B., Isoniemi H., Broome U., Olausson M., Backman L., Hansen B., et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 40 (2004) 815-822
127. Boberg K.M., Bergquist A., Mitchell S., Pares A., Rosina F., Broome U., et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 37 (2002) 1205-1211
128. Leidenius M., Hockersted K., Broome U., Ericzon B.G., Friman S., Olausson M., et al. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. J Hepatol 34 (2001) 792-798
129. Ramage J.K., Donaghy A., Farrant J.M., Iorns R., and Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108 (1995) 865-869
130. Levy C., Lymp J., Angulo P., Gores G.J., Larusso N., and Lindor K.D. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 50 (2005) 1734-1740
131. Bjornsson E., Kilander A., and Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19 (1999) 501-508
132. Petersen-Benz C., and Stiehl A. Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis. Z Gastroenterol 43 (2005) 587-590
133. Lempinen M., Isoniemi H., Makisalo H., Nordin A., Halme L., Arola J., et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 47 (2007) 677-683
134. Campbell W.L., Ferris J.V., Holbert B.L., Thaete F.L., and Baron R.L. Biliary tract carcinoma complicating primary sclerosing cholangitis: evaluation with CT, cholangiography, US, and MR imaging. Radiology 207 (1998) 41-50
135. Prytz H., Keiding S., Bjornsson E., Broome U., Almer S., Castedal M., et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44 (2006) 1572-1580
136. Buckles D.C., Lindor K.D., Larusso N.F., Petrovic L.M., and Gores G.J. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 97 (2002) 1138-1142
137. Bergquist A., and Broome U. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15 (2001) 643-656
138. Boberg K.M., Jebsen P., Clausen O.P., Foss A., Aabakken L., and Schrumpf E. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 45 (2006) 568-574
139. Ponsioen C.Y., Vrouenraets S.M., van Milligen de Wit A.W., Sturm P., Tascilar M., Offerhaus G.J., et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 31 (1999) 305-309
140. Lindberg B., Arnelo U., Bergquist A., Thorne A., Hjerpe A., Granqvist S., et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 34 (2002) 909-916
141. Ponchon T., Gagnon P., Berger F., Labadie M., Liaras A., Chavaillon A., et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest Endosc 42 (1995) 565-572
142. Tischendorf J.J., Kruger M., Trautwein C., Duckstein N., Schneider A., Manns M.P., et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 38 (2006) 665-669
143. Chen Y.K., and Pleskow D.K. SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest Endosc 65 (2007) 832-841
144. Tischendorf J.J., Meier P.N., Schneider A., Manns M.P., and Kruger M. Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand J Gastroenterol 42 (2007) 1011-1017
145. Kubicka S., Kuhnel F., Flemming P., Hain B., Kezmic N., Rudolph K.L., et al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 48 (2001) 403-408
146. Alvaro D., Macarri G., Mancino M.G., Marzioni M., Bragazzi M., Onori P., et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med 147 (2007) 451-459
147. Ponsioen C.Y., Vrouenraets S.M., Prawirodirdjo W., Rajaram R., Rauws E.A., Mulder C.J., et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51 (2002) 562-566
148. Ekbom A., Helmick C., Zack M., and Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323 (1990) 1228-1233
149. Aadland E., Schrumpf E., Fausa O., Elgjo K., Heilo A., Aakhus T., et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 22 (1987) 655-664
150. Brentnall T.A., Haggitt R.C., Rabinovitch P.S., Kimmey M.B., Bronner M.P., Levine D.S., et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110 (1996) 331-338
151. Broome U., Lindberg G., and Lofberg R. Primary sclerosing cholangitis in ulcerative colitis - a risk factor for the development of dysplasia and DNA aneuploidy?. Gastroenterology 102 (1992) 1877-1880
152. Kornfeld D., Ekbom A., and Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41 (1997) 522-525
153. Shetty K., Rybicki L., Brzezinski A., Carey W.D., and Lashner B.A. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94 (1999) 1643-1649
154. Broome U., Lofberg R., Veress B., and Eriksson L.S. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22 (1995) 1404-1408
155. Kiesslich R., Fritsch J., Holtmann M., Koehler H.H., Stolte M., Kanzler S., et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124 (2003) 880-888
156. Hurlstone D.P., McAlindon M.E., Sanders D.S., Koegh R., Lobo A.J., and Cross S.S. Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 126 (2004) 376-378
157. LaRusso N.F., Shneider B.L., Black D., Gores G.J., James S.P., Doo E., et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 44 (2006) 746-764
158. Okolicsanyi L., Fabris L., Viaggi S., Carulli N., Podda M., and Ricci G. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 8 (1996) 685-691
159. Farrant J.M., Hayllar K.M., Wilkinson M.L., Karani J., Portmann B.C., Westaby D., et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100 (1991) 1710-1717
160. Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., and Chapman R.W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121 (2001) 900-907
161. Harnois D.M., Angulo P., Jorgensen R.A., Larusso N.F., and Lindor K.D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96 (2001) 1558-1562
162. Rost D., Rudolph G., Kloeters-Plachky P., and Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40 (2004) 693-698
163. Olsson R., Boberg K.M., de Muckadell O.S., Lindgren S., Hultcrantz R., Folvik G., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129 (2005) 1464-1472
164. Pardi D.S., Loftus Jr. E.V., Kremers W.K., Keach J., and Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124 (2003) 889-893
165. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134 (2001) 89-95
166. van Hoogstraten H.J., Vleggaar F.P., Boland G.J., van Steenbergen W., Griffioen P., Hop W.C., et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 95 (2000) 2015-2022
167. Boberg K.M., Fausa O., Haaland T., Holter E., Mellbye O.J., Spurkland A., et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 23 (1996) 1369-1376
168. Beuers U., and Rust C. Overlap syndromes. Semin Liver Dis 25 (2005) 311-320
169. Stiehl A. Primary sclerosing cholangitis: the role of endoscopic therapy. Semin Liver Dis 26 (2006) 62-68
170. Stiehl A., and Rost D. Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis. Clin Rev Allergy Immunol 28 (2005) 159-165
171. Bjornsson E., Lindqvist-Ottosson J., Asztely M., and Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 99 (2004) 502-508
172. Johnson G.K., Geenen J.E., Venu R.P., Schmalz M.J., and Hogan W.J. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 37 (1991) 38-43
173. Lombard M., Farrant M., Karani J., Westaby D., and Williams R. Improving biliary-enteric drainage in primary sclerosing cholangitis: experience with endoscopic methods. Gut 32 (1991) 1364-1368
174. Linder S., and Soderlund C. Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer. Hepatogastroenterology 48 (2001) 387-392
175. Baluyut A.R., Sherman S., Lehman G.A., Hoen H., and Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 53 (2001) 308-312
176. Wagner S., Gebel M., Meier P., Trautwein C., Bleck J., Nashan B., et al. Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy 28 (1996) 546-551
177. Allison M.C., Burroughs A.K., Noone P., and Summerfield J.A. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J Hepatol 3 (1986) 118-122
178. Awadallah N.S., Chen Y.K., Piraka C., Antillon M.R., and Shah R.J. Is there a role for cholangioscopy in patients with primary sclerosing cholangitis?. Am J Gastroenterol 101 (2006) 284-291
179. Wiesner R.H., Porayko M.K., Dickson E.R., Gores G.J., LaRusso N.F., Hay J.E., et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 16 (1992) 1290-1299
180. Rea D.J., Heimbach J.K., Rosen C.B., Haddock M.G., Alberts S.R., Kremers W.K., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242 (2005) 451-458
181. Sudan D., DeRoover A., Chinnakotla S., Fox I., Shaw Jr. B., McCashland T., et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2 (2002) 774-779
182. Graziadei I.W., Wiesner R.H., Marotta P.J., Porayko M.K., Hay J.E., Charlton M.R., et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30 (1999) 1121-1127
183. Graziadei I.W., Wiesner R.H., Batts K.P., Marotta P.J., LaRusso N.F., Porayko M.K., et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29 (1999) 1050-1056
184. Nathan H., Pawlik T.M., Wolfgang C.L., Choti M.A., Cameron J.L., and Schulick R.D. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11 (2007) 1488-1496
185. Jonas S., Benckert C., Thelen A., Lopez-Hanninen E., Rosch T., and Neuhaus P. Radical surgery for hilar cholangiocarcinoma. Eur J Surg Oncol (2007) 23
186. Mantel H.T., Rosen C.B., Heimbach J.K., Nyberg S.L., Ishitani M.B., Andrews J.C., et al. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl 13 (2007) 1372-1381
187. Ortner M.E., Caca K., Berr F., Liebetruth J., Mansmann U., Huster D., et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125 (2003) 1355-1363
188. Crescenzi E., Chiaviello A., Canti G., Reddi E., Veneziani B.M., and Palumbo G. Low doses of cisplatin or gemcitabine plus photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol Cancer Ther 5 (2006) 776-785
189. Malek N.P., Greten T., and Kubicka S. Systemic treatment of liver and biliary tumors. Internist (Berl) 48 (2007) 46-49